Figure 7. (A) Cell viability assessed by the MTS assay FEMX-1 (black bars) and WM239 cells (white bars) treated with 0.75 μg/ml lexatumumab and 40 nM anisomycin alone or in combination with 2.5 μM of the p38 MAPK inhibitor SB203580 for 24 h. (B) Immuno-blot evaluation of p38 pathway inhibition. FEMX-1 and WM239 cells were treated with 2.5 and 5 μM of the p38 inhibitor SB203580, 0.75 μg/ml lexatumumab and 40 nM anisomycin alone or in combination for 24 h.